Tarsus appoints former Allergan CEO David Pyott to Board of Directors

Tarsus Pharmaceuticals, Inc.

Pyott appointed as Class III director effective Feb 18, 2026; term expires at 2026 annual meeting.
He chairs Commercial Committee and serves on Nominating and Compensation Committees; deemed independent.
Initial equity grant target $540,000 (50% options, 50% RSUs) under non-employee director policy.
Pyott served as Allergan CEO for 17 years, grew revenue from ~$1B to >$7B; also on Alnylam and Pliant boards.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.